Regeneron spent most of 2024 and 2025 telling investors a story about transition: EYLEA, its aging eye-injection blockbuster, was losing ground to biosimilar copies, but Dupixent, the allergy-and-inflammation drug it co-markets with Sanofi, was growing fast enough to carry the company through. Management said the math would work. The filings mostly agreed, with some important asterisks. Now, with a full earnings call scheduled for October 30, 2026, the ledger is open and the claims are due for a reckoning.
This piece is that ledger. Each section takes a load-bearing claim from management’s public record, holds it against the filed numbers, and delivers a verdict. The Q3 2026 results are not yet public, so the most recent filed data is the 10-Q for the quarter ended June 30, 2026. Where the evidence runs out, we say so.
First, the shape of it
The filed numbers show a company that earns about thirty-one cents on every dollar of revenue, steady for two years, but growing total sales at barely one percent annually. The stock trades at a price-to-earnings multiple of 15.2, just below its own decade median of 15.9, meaning the market is paying a near-average price for what looks like a below-average growth moment. The open question is whether Dupixent’s accelerating profits, freed from a now-repaid debt to Sanofi, can restart revenue growth before EYLEA’s decline becomes the dominant story.
Claim 1: “Dupixent is the growth engine”
Management has said this, in various forms, on every earnings call since 2022. The filings vote yes, emphatically. Full-year 2025 results show Dupixent’s global net sales surging 26% to $17.8 billion, a figure that dwarfs Regeneron’s total reported revenue because Sanofi books the sales and Regeneron receives a collaboration profit share. In Q2 2026, Dupixent worldwide sales reached $6.0 billion for the quarter alone, annualizing at a pace that would make it one of the best-selling drugs on earth.
The verdict here is straightforward: the claim holds. Dupixent is doing what management said it would do. The more interesting question is whether Regeneron captures enough of that growth in its own reported line, which brings us to the next claim.
Dupixent’s trajectory is now the company’s single largest revenue contributor; how that momentum translates into reported earnings is the variable the filed numbers will need to confirm over coming quarters.
Claim 2: “The Sanofi balance repayment will meaningfully boost profits”
This one is specific and testable. Regeneron and Sanofi have a decades-old collaboration under which Sanofi fronted development costs that Regeneron was required to repay from its share of Dupixent profits, a running tab called the Sanofi Development Balance. Management stated in the Q2 2026 report, announced July 30, 2026, that this balance was fully repaid by the end of Q2, and that starting in Q3, Regeneron would keep a larger share of every Dupixent dollar.
Think of it this way: a business that has been paying off a silent partner’s loan finally clears the debt. The revenue line does not change, but the owner’s take-home does. The October 30 call will be the first time investors see that larger cut in actual filed numbers. The claim is credible on its face, the mechanism is real, and the Q2 filing confirms the repayment occurred. The verdict is pending, but the setup is exactly as described.
This is probably the most consequential thing October 30 will deliver, because it converts a promise into a proof.
Claim 3: “EYLEA HD is the answer to biosimilar pressure”
This is where the ledger gets complicated. Management’s argument has been that EYLEA HD, a higher-dose version of the original drug requiring fewer injections, would hold patients and physicians even as cheaper biosimilar copies of the original EYLEA flooded the market. The filed record gives a split verdict.
On the positive side, Q1 2026 results show EYLEA HD U.S. net sales of $468 million, up 52% year over year, real, substantial growth. On the negative side, original EYLEA U.S. sales fell by more than a third in the same period, and the Q2 2026 10-Q shows the original still shrinking. The two products together are losing ground. FiercePharma reported that Celltrion’s biosimilar is cleared for U.S. launch by end of 2026, and Sandoz’s copy is also cleared for an end-of-2026 launch, joining Amgen’s version already on shelves since October 2024.
The verdict: EYLEA HD is growing, but not fast enough yet to offset the original’s decline. Management’s claim is partially true and structurally optimistic. The full-year 2025 filing shows the combined U.S. EYLEA franchise fell by more than a quarter. That is the filed reality behind the transition narrative.
Claim 4: “The pipeline is deep enough to absorb setbacks”
Regeneron has long argued that its genetics-driven research engine produces enough shots on goal that any single failure is manageable. The 2024 to 2025 record tests that claim hard. The 2025 10-K discloses FDA Complete Response Letters (a CRL is the agency’s way of saying “not yet” to an approval application) for both odronextamab in follicular lymphoma and linvoseltamab in multiple myeloma. Then, in May 2026, the Phase 3 trial for fianlimab combined with Libtayo in first-line melanoma failed to hit its primary endpoint, triggering a securities class-action lawsuit alleging that management made misleading statements about the program’s prospects.
Three significant setbacks in roughly eighteen months is not a crisis for a company with Regeneron’s balance sheet, but it is a stress test for the “deep pipeline” claim. The honest verdict is that the claim is structurally true, the pipeline is genuinely broad, but the recent failure rate is higher than management’s optimistic framing suggested. The October 30 call will be an opportunity to hear how management characterizes the remaining pipeline, and the filed record is the right tool for checking whatever they say.
In the analytical framework here, the pipeline’s hit rate over the next two years is a more structurally significant variable than any single quarter’s revenue figure.
Reading the numbers
- $14.3 billion: FY2025 total revenue. This is what Regeneron reported as its own top line in the 2025 annual filing, up just 1% from 2024. It means the company grew about as fast as inflation, despite Dupixent’s 26% surge, because EYLEA’s decline ate most of the gain. A household budget analogy: one income rose sharply, the other fell sharply, and the family’s total take-home barely moved.
- 31.4%: FY2025 net margin. For every dollar Regeneron collected in revenue, it kept about thirty-one cents as profit after all costs. That is stable, two years running, and well above the average large pharmaceutical company. It means the business is not deteriorating underneath, even as the product mix shifts.
- $4.3 billion: Q2 2026 total revenue. This is the most recent filed quarter. The acceleration from the full-year 1% growth rate reflects stronger Dupixent collaboration income; the larger profit-share benefit from the fully repaid Sanofi Development Balance does not begin flowing until Q3 2026, making October 30 the first real test of that uplift.
- 15.2: current price-to-earnings multiple (calculated from filed EPS and closing price as of June 30, 2026; see BullScope valuation methodology). A multiple is the price tag per dollar of annual profit. At 15.2, investors are paying $15.20 for each dollar Regeneron earns per year. The company’s own decade median is 15.9, so today’s price is slightly below average for this stock’s own history. That gap is not dramatic; it reflects a market that has not yet seen the Dupixent profit-share acceleration in filed numbers, making the October 30 results the next material data point for assessing whether the valuation reflects the transition’s progress.
- $6.0 billion: Dupixent global net sales in Q2 2026 alone. Sanofi records this figure; Regeneron receives a profit share. To feel the scale: $6.0 billion in a single quarter is more than Regeneron’s entire company earned in revenue during any quarter in its history before Dupixent reached scale. The drug is now larger than the company that invented it, by most measures.
For the standing yardsticks on Regeneron Pharmaceuticals: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Regeneron Pharmaceuticals.
Sources
- Regeneron 10-Q, quarter ended June 30, 2026
- Regeneron 10-Q, quarter ended March 31, 2026
- Regeneron 10-K, fiscal year ended December 31, 2025
- Regeneron Q2 2026 earnings release, GlobeNewswire, July 30, 2026
- Regeneron Q3 2026 reporting date announcement, InvestingNews
- FiercePharma: Regeneron-Celltrion EYLEA biosimilar settlement
- FiercePharma: Sandoz EYLEA biosimilar settlement
- ZLK: Regeneron securities class-action lawsuit, fianlimab trial failure
- BioSpace: Regeneron regulatory and manufacturing setbacks, 2024 to 2025
